| abstract |
The present invention is a new DGAT1 inhibitor, especially the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, its preparation method, pharmaceutical composition and its use in the prevention and treatment of familial chymemia syndrome ( FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia. |